• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?

作者信息

Boutari Chrysoula, Athyros Vasilios G

机构信息

Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.

出版信息

Angiology. 2024 Mar;75(3):205-207. doi: 10.1177/00033197231201706. Epub 2023 Sep 10.

DOI:10.1177/00033197231201706
PMID:37691291
Abstract
摘要

相似文献

1
The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?肝脏组织学与心血管风险之间的关联：是时候在高危患者群体中引入脂肪性肝病筛查了吗？
Angiology. 2024 Mar;75(3):205-207. doi: 10.1177/00033197231201706. Epub 2023 Sep 10.
2
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations.评估烟酰胺腺嘌呤二核苷酸（NAD）补充剂在治疗代谢功能障碍相关脂肪性肝病中的疗效：关键考量因素。
Clin Mol Hepatol. 2024 Jul;30(3):582-584. doi: 10.3350/cmh.2023.0555. Epub 2023 Dec 29.
3
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.代谢功能障碍相关脂肪性肝病：诊断与管理的近期转折点
Metabolism. 2024 Aug;157:155936. doi: 10.1016/j.metabol.2024.155936. Epub 2024 May 17.
4
Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.拥抱变革：在脂肪性肝病范畴下，从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病
Clin Gastroenterol Hepatol. 2024 Jan;22(1):9-11. doi: 10.1016/j.cgh.2023.09.034. Epub 2023 Oct 15.
5
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.回复：“从非酒精性脂肪性肝病到代谢相关脂肪性肝病：新定义的前景与陷阱”：欧洲肝脏研究学会（EASL）、美国肝病研究学会（AASLD）和阿卜杜勒阿齐兹国王肝脏研究与移植中心（ALEH）联合起来推动脂肪性肝病领域的发展。
J Hepatol. 2024 Jul;81(1):e20-e21. doi: 10.1016/j.jhep.2023.10.008. Epub 2023 Dec 19.
6
In response to: Steatotic liver disease-know your enemies.回应：脂肪性肝病——了解你的敌人。
Clin Mol Hepatol. 2024 Apr;30(2):284-286. doi: 10.3350/cmh.2024.0108. Epub 2024 Feb 19.
7
[Not Available].[无可用内容]。
Ugeskr Laeger. 2024 May 6;186(19):V12230778. doi: 10.61409/V12230778.
8
Reply to: Correspondence on "clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease'.回复：关于“代谢功能障碍相关脂肪性肝病和非酒精性脂肪性肝病的临床特征及死亡率相似”的通信
J Hepatol. 2024 Oct;81(4):e160-e161. doi: 10.1016/j.jhep.2024.05.024. Epub 2024 May 23.
9
Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.心血管危险因素和代谢综合征与非酒精性和酒精性脂肪性肝病的关系：一项回顾性分析。
BMC Endocr Disord. 2021 May 1;21(1):91. doi: 10.1186/s12902-021-00758-x.
10
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.非酒精性脂肪性肝病与心血管风险：美国心脏协会的科学声明
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.

引用本文的文献

1
Targeting Insulin Resistance and Liver Fibrosis: CKD Screening Priorities in MASLD.针对胰岛素抵抗和肝纤维化：非酒精性脂肪性肝病相关慢性肾脏病的筛查重点
Biomedicines. 2025 Apr 1;13(4):842. doi: 10.3390/biomedicines13040842.
2
Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study.土耳其代谢功能障碍相关脂肪性肝病和脂肪性肝炎的患病率：一项法医尸检研究。
Heliyon. 2024 Jul 20;10(15):e34915. doi: 10.1016/j.heliyon.2024.e34915. eCollection 2024 Aug 15.